Indoco Q1 profit hinges on ₹97 cr ophthalmic sale gain
Standalone revenue up 6% to ₹408 cr, but pre-tax loss of ₹4.1 cr before exceptional items. EBITDA margin improves to 10.3% but core business under pressure.
— 2 earlier stories on Indoco Remedies Ltd. →What's new
- Standalone revenue up 6% YoY to ₹408 cr, but pre-tax loss of ₹4.1 cr before exceptional items.
- Net profit of ₹82.3 cr entirely from one-time gain of ₹97.3 cr from ophthalmic sale.
- EBITDA margin at 10.3% improved from 3.8% last year but down from 14.7% in Q4.
Why this matters
The profit is non-recurring; without the sale gain, the core business would have reported a loss. Investors should focus on underlying operational trends, not the headline number.
What we're watching
- Revenue growth trajectory in domestic vs international segments.
- Margin trends without one-time gains – can EBITDA sustain above 10%?
- Any new strategic initiatives post-ophthalmic sale.
The full read
Indoco's ₹82.3 cr standalone profit is a mirage. Strip out the ₹97.34 cr exceptional gain from selling its ophthalmic unit to Sunways India and the business actually lost ₹4.12 cr before tax. Revenue grew 6% to ₹408 cr — international led the way, up 11% to ₹180 cr, while domestic sales crawled 2% higher. EBITDA margin of 10.3% is better than the 3.8% last year, but well off the 14.7% of the March quarter. The sale is done; the cash is in. Now the company must prove it can generate sustainable profits from the remaining business. This quarter suggests that work is still underway.
Questions answered
- What drove Indoco's Q1 profit?
- The ₹82.3 cr standalone profit is entirely due to a one-time exceptional gain of ₹97.34 cr from the slump sale of the ophthalmic division to Sunways India. Without this, the company would have reported a pre-tax loss of ₹4.12 cr.
- How is the core business performing operationally?
- Core operations remain under pressure. Revenue grew 6% to ₹408 cr, but the business posted a pre-tax loss of ₹4.1 cr before exceptional items. Domestic sales edged up just 2%, while international revenue grew 11% to ₹180 cr.
- What is the trend in EBITDA margins?
- EBITDA margin improved to 10.3% from 3.8% a year ago, but it declined from 14.7% in the preceding March quarter, indicating sequential pressure.
- Is the ophthalmic division sale complete?
- Yes, the sale to Sunways India was completed in the preceding quarter, and the gain is now reflected in these results. The transaction was previously disclosed by the company.
- What should investors watch going forward?
- Key metrics are organic revenue growth, especially in domestic formulations, and the ability to sustain EBITDA margins without one-time gains. The international segment's recovery is a positive sign but needs to be built upon.
Story so far
All notes on INDOCO →- 28 Jul 2026 · 12:01 PM IST Indoco Q1 profit hinges on ₹97 cr ophthalmic sale gain
- today Indoco cuts debt target, USFDA audit still open
- today Indoco's ₹97 cr sale masks core loss; auditor flags subsidiary's future